(Reuters) — The U.S. government signed a $450 million contract with Regeneron Pharmaceuticals Inc (REGN.O) for its potential COVID-19 antibody cocktail, the drugmaker said on Tuesday.
U.S. signs $450 million contract with Regeneron for COVID-19 therapy
Posted in biotech/medical, government